A Study to Assess CD19-targeted Immunotherapy T Cells in Patients With Relapsed or Refractory CD19+ B Cell Leukemia
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02672501 |
|
Recruitment Status : Unknown
Verified February 2016 by Shanghai GeneChem Co., Ltd..
Recruitment status was: Recruiting
First Posted : February 3, 2016
Last Update Posted : February 3, 2016
|
Sponsor:
Shanghai GeneChem Co., Ltd.
Information provided by (Responsible Party):
Shanghai GeneChem Co., Ltd.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Unknown |
|---|---|
| Estimated Primary Completion Date : | June 2018 |
| Estimated Study Completion Date : | December 2019 |